---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-140591"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:33:53.012488+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Erasca signs Joyo/Medshine licenses for pan-RAS/KRAS; cuts 18% staff, deprioritizes ERAS-007

## Summary
- In-licensed pan-RAS inhibitor from Joyo for $12.5M upfront + up to $176.5M milestones; lead candidate ERAS-0015.
- In-licensed pan-KRAS inhibitor from Medshine for $10M upfront + up to $160M milestones; lead candidate ERAS-4001.
- Workforce reduction of ~18% primarily in drug discovery; estimated $2.2M charges in Q2 2024.
- Discontinuing internal ERAS-4 pan-KRAS program; deprioritizing ERAS-007 due to insufficient efficacy data and ERAS-801.
- Pipeline focus on naporafenib, ERAS-0015, and ERAS-4001.

## SEC filing metadata
- accession: 0001193125-24-140591
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/0001193125-24-140591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/d832290d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-140591
- JSON: https://secwatch.observer/filing/0001193125-24-140591.json
- Plain text: https://secwatch.observer/filing/0001193125-24-140591.txt

## Source-grounded claims
- claim_id: 7b75c6f02e39f768ede7526a6aef9a20ad9ea42d
  claim: Erasca, Inc. entered into Medshine License Agreement with Medshine Discovery Inc. valued at $10.0 million (effective 2024-05-14).
  evidence_excerpt: On May 14, 2024, the Company entered into an exclusive license agreement (the “Medshine License Agreement”) with Medshine Discovery Inc. (“Medshine”) under which the Company was granted an exclusive, worldwide, royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Medshine to develop, manufacture and commercialize certain pan-KRAS inhibitors in all fields of use.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/0001193125-24-140591-index.htm
- claim_id: e1681ad411f6b591c42ee4a0ab36d03ce929a03a
  claim: Erasca, Inc. entered into Joyo License Agreement with Guangzhou Joyo Pharmatech Co., Ltd. valued at $12.5 million (effective 2024-05-14).
  evidence_excerpt: On May 14, 2024, Erasca, Inc. (the “Company”) entered into an exclusive license agreement (the “Joyo License Agreement”) with Guangzhou Joyo Pharmatech Co., Ltd. (“Joyo”) under which the Company was granted an exclusive, worldwide (except mainland China, Hong Kong and Macau), royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Joyo to develop, manufacture, and commercialize certain pan-RAS inhibitors in all fields of use.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/0001193125-24-140591-index.htm
- claim_id: 3f289dc7d6fd9edc2b3a0271c43f82964ee75cb7
  claim: Erasca, Inc. announced a restructuring with charges of approximately $2.2 million affecting drug discovery functions or on the deprioritized programs (by approximately 18%).
  evidence_excerpt: by approximately 18%, primarily affecting employees working in drug discovery functions or on the deprioritized programs. The Company anticipates recognizing approximately $2.2 million in total charges in the second quarter of 2024 in connection with the reduction in force. These charges will consist primarily of one-time cash charges for termination benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/0001193125-24-140591-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.